---

---

tags : Therapy    entities : Compass pathways plc   

save search

---

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study
Published: 2023-05-30 (Crawled : 18:00) - biospace.com/
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| 9.54% | O: 0.0% H: 1.96% C: -2.48%
comp360 depression research psilocybin therapy study

---

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023
Published: 2023-05-26 (Crawled : 11:00) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| 12.03% | O: 2.67% H: 1.69% C: -0.39%
comp360 asco cancer depression psilocybin therapy

---

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
Published: 2022-12-08 (Crawled : 10:00) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -23.19% | O: 1.83% H: 0.63% C: -8.91%
comp360 potential therapy study psilocybin

---

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022
Published: 2022-10-12 (Crawled : 22:00) - biospace.com/
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -28.25% | O: -2.4% H: 2.11% C: -5.44%
comp360 day treatment program therapy depression psilocybin

---

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Published: 2022-07-28 (Crawled : 09:00) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -47.82% | O: 1.81% H: 3.98% C: -1.04%
trial therapy psilocybin

---

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -2.33% | O: -3.15% H: 2.29% C: -3.37%
therapy psilocybin

---

COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
Published: 2022-05-03 (Crawled : 19:00) - biospace.com/
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -14.49% | O: -0.41% H: 0.41% C: -1.95%
comp360 potential therapy depression psilocybin

---

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
Published: 2022-01-19 (Crawled : 12:30) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -51.59% | O: 0.17% H: 2.94% C: -3.69%
treatment eye potential therapy depression psilocybin

---

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -68.25% | O: -5.04% H: 0.0% C: 0.0%
comp360 treatment positive therapy depression psilocybin

---

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Published: 2021-12-01 (Crawled : 12:30) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -74.4% | O: 6.29% H: 0.0% C: -8.02%
treatment comp360 trial positive results positive therapy results depression psilocybin

---

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Published: 2021-11-09 (Crawled : 12:15) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -83.01% | O: -17.57% H: 3.31% C: -11.45%
treatment positive therapy results topline depression trial comp360 psilocybin

---

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
Published: 2021-11-03 (Crawled : 12:15) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -80.76% | O: 3.74% H: 1.26% C: 0.35%
therapy trial comp360 psilocybin

---

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
Published: 2021-10-20 (Crawled : 13:15) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -75.19% | O: 2.13% H: 2.17% C: 0.7%
therapy cancer depression comp360 psilocybin

---

COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy
Published: 2021-02-03 (Crawled : 12:03) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K |

Health Technology

| -80.4% | O: 1.15% H: 9.78% C: 5.53%
therapy train psilocybin

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---